About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Competition Commission of India Extends Deadline for Bids to Conduct Pharma Study

by Vishnuprasad on October 19, 2015 at 6:21 PM
Font : A-A+

Competition Commission of India Extends Deadline for Bids to Conduct Pharma Study

The Competition Commission of India, which is responsible for enforcing The Competition Act, 2002, has extended the deadline for submitting bids to carry out a detailed study of pharma and healthcare services sector in the national capital region.

The Act prohibits anti-competitive agreements, abuse of dominant position by enterprises and regulates combinations, which causes or likely to cause an appreciable adverse effect on competition within India.

Advertisement

The anti-trust regulator is planning the study to understand whether there are unfair practices in this sector as part of larger efforts to clamp down on anti-competitive business practices and has also passed many orders in this regard.

In recent years, CCI has come across various instances in the pharmaceutical sector where competition norms seem to have been violated.

Entities interested in conducting "baseline study/ survey in the pharmaceutical sector and healthcare delivery system/ services in Delhi & NCR region," for Competition Commission of India (CCI) can now submit their bids till November 5.
Advertisement

The earlier deadline for submission of bids ended on October 17.

Under the proposed study, public and private hospitals, insurance companies, pharmaceutical firms and their associations, doctors and their associations, among others, would be covered.

While inviting Expression of Interest (EOI) in September, the watchdog had said that it came across various issues in pharmaceutical sector and healthcare delivery systems/ services.

These include "non-availability of essential medicines, increasing price of drugs, nexus between pharmaceutical companies and pharmacists, nexus between pharmacists and doctors, nexus between doctors and pathological laboratories, nexus between doctors and pharmaceutical companies, and nexus between hospitals and insurance companies etc", it had said.

As per CCI, the primary objective of the baseline study/ survey is to collect information and credible evidences on competition issues in the concerned sector and present the same in an analytical manner.



Source: PTI
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity 

Most Popular on Medindia

Drug - Food Interactions Drug Side Effects Calculator Accident and Trauma Care Loram (2 mg) (Lorazepam) Noscaphene (Noscapine) Blood Pressure Calculator A-Z Drug Brands in India Daily Calorie Requirements Vent Forte (Theophylline) Iron Intake Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Competition Commission of India Extends Deadline for Bids to Conduct Pharma Study Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests